Advertisement

Diagnosing FSGS as a Pattern of Injury, With Astrid Weins, MD, PhD

Published on: 

A renal pathologist explains how biopsy findings, clinical context, anti-nephrin antibodies and genetics shape FSGS workup.

Focal segmental glomerulosclerosis (FSGS) describes a pattern of injury that follows podocyte loss rather than a single disease, and interpreting a biopsy depends as much on the patient’s clinical status as on the tissue.¹ As antibody and genetic testing mature, the field may need a classification that sorts patients by cause.

Astrid Weins, MD, PhD, chief of integrated renal pathology at Mass General Brigham, moderated an educational symposium on FSGS at American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, with nephrologists Jai Radhakrishnan, MD, MS, of Columbia University Irving Medical Center, and Vladimir Tesar, MD, PhD, of Charles University in Prague. In an interview with HCPLive, she described how she reads an FSGS biopsy as a pathologist and what the clinicians on her panel want in hand before they treat a patient with nephrotic syndrome.

Why FSGS Is a Pattern of Podocyte Injury, Not a Diagnosis

“It’s a pattern of injury that we see as a consequence of podocyte loss in a variety of different conditions that can be acquired and can be genetic, that can be adaptive, compensatory,” Weins said. “So we have to be very clear what it is that we’re seeing.”

For that reason, Weins gives the histology and the clinical scenario at the time of biopsy equal weight. A patient in active nephrotic syndrome points her toward a diffuse podocytopathy, since a more limited injury would generally not produce overtly nephrotic-range proteinuria. She said a fully definitive diagnosis is not always possible.

How Light Microscopy, Immunofluorescence and Electron Microscopy Guide FSGS Workup

On light microscopy, Weins counts the glomeruli and notes how many show segmental scarring, how many show global scarring and what other features are present. Immunofluorescence adds little in most cases. The exception is immune-mediated podocytopathy, such as disease driven by anti-nephrin antibodies, where a fine granular IgG “dusting” can appear over the podocytes.

Electron microscopy is where she looks at foot process effacement, specifically in a glomerulus that is not affected by segmental sclerosis.

“If it’s diffuse foot process effacement and you see absence of slit diaphragms, then you can be reasonably sure that this is a primary form of podocyte injury,” Weins said. From there, she weighs whether the injury looks immune-mediated or potentially toxic, and makes or suggests that diagnosis in her report.

What FSGS Variants Like Tip Lesion and Perihilar Sclerosis Signal

Weins treats classification as one part of diagnosis. The tip lesion variant usually develops in the acute phase of nephrotic syndrome and can scar over time, so it leans a case toward the diffuse podocytopathy category rather than adaptive injury. Perihilar glomerulosclerosis is more likely to be connected to vascular disease.

“A classification is only worth something in the context of all these other things,” she said.

Anti-Nephrin Antibodies and Genetic Testing Could Reshape FSGS Classification

Weins believes the field needs a new classification that includes autoimmune-mediated podocyte injury, which clinicians have not been able to diagnose reliably until now. Her group’s 2022 discovery of anti-nephrin autoantibodies in minimal change disease was the first to define that condition as autoimmune.² Later studies have also linked circulating antinephrin autoantibodies to disease activity in minimal change disease and primary FSGS, although prevalence estimates have varied across cohorts and assays.³

In Weins’ view, anti-nephrin antibody testing, which may become available in the near future, could recategorize some patients with diffuse podocytopathies and FSGS, at least during the acute phase of disease.

Genetic causes can already be classified. When an FSGS pattern appears on biopsy, Weins recommends testing for variants in podocyte genes and in basement membrane genes, which may affect how well podocytes survive stress.

“Genetic FSGS, or at least vulnerabilities of podocytes, can already influence how you diagnose FSGS in the biopsy,” Weins said. “But often this information is not available to us at the time of biopsy and will be actually done after.”

What Nephrologists Want Before Treating Nephrotic Syndrome in FSGS

To close the session, Weins asked Radhakrishnan and Tesar what they want to see when they approach a patient with nephrotic syndrome. Both named an immune profile that includes anti-nephrin antibody testing, a biopsy and a clinical history covering whether the disease is acute or chronic, the level of proteinuria and serum albumin. Ideally, they would also have genetic testing for every patient.

“I think that would be a very good starting point for understanding where this patient is in the journey and how they could be best helped by therapeutic approaches,” Weins said.

Editor’s Note: Weins reports relevant disclosures with Vera Therapeutics, Sysmex, and Novartis.

References
  1. Weins A, Radhakrishnan J, Tesar V. Advances in treatment and management of FSGS. Educational symposium presented at: American Society of Nephrology Kidney Week 2026; October 22, 2026; Denver, CO.
  2. Mass General Brigham. Shedding new light on a rare form of proteinuric kidney disease. Accessed November 18, 2026. https://www.massgeneralbrigham.org/en/about/newsroom/articles/rare-form-proteinuric-kidney-disease
  3. Antinephrin autoantibodies could aid in predicting disease activity in nephrotic syndrome. HCPLive. Accessed November 18, 2026. https://www.hcplive.com/view/antinephrin-antibodies-could-aid-in-predicting-disease-activity-in-nephrotic-syndrome

Advertisement
Advertisement